#MYQORZO
LightNews LightNews
bgrrl.bsky.social
FDA approved today! Second in class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy.

#HCM
#Cardiomyopathy
#CardioSky
#MedSky
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approv...
ir.cytokinetics.com
December 20, 2025 at 12:00 AM
jamesrpriestmd.bsky.social
Pretty good results from Cytokinetics this morning on Myqorzo/aficamten in non-obstructive HCM. (Full disclosure recently worked there but not on the clinical development team) #cardiosky
May 5, 2026 at 8:33 PM
merlintrader.bsky.social
Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion

https://merlintrader.com/cytokinetics-incorporated-stock-hub/
Cytokinetics ($CYTK) Stock Hub: ACACIA, MAPLE, MYQORZO
Cytokinetics ($CYTK) Stock Hub updated Aug. 29, 2026: ACACIA-HCM and MAPLE-HCM analyses, MYQORZO launch, Nov. 14 PDUFA, cash and risks.
merlintrader.com
September 18, 2026 at 10:54 AM
medpagetoday.com
The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.
https://www.medpagetoday.com/cardiology/chf/119130
New Drug Approved for Hypertrophic Cardiomyopathy
Aficamten improved exercise capacity in trial, carries less burdensome labeling
www.medpagetoday.com
December 23, 2025 at 12:15 AM
rleutybiotech.bsky.social
Cytokinetics plans $650 million stock sale to fund heart drug's continued launch
www.bizjournals.com/sanfrancisco...
Fresh off big clinical trial win, Cytokinetics looks to raise about $650 million - San Francisco Business Times
Cytokinetics to sell $650M in stock to fund Myqorzo heart drug launch after shares rose 16% on promising clinical trial results.
www.bizjournals.com
May 6, 2026 at 5:20 PM
rleutybiotech.bsky.social
Cytokinetics wins China approval for heart-failure drug Myqorzo - San Francisco Business Times bizjournals.com/sanfrancisco...
On cusp of FDA and European decisions, Cytokinetics heart drug wins approval in China - San Francisco Business Times
On cusp of FDA and European decisions, Cytokinetics' heart drug has won approval in China.
bizjournals.com
December 17, 2025 at 5:43 PM
endpts.com
Braveheart Bio priced an upsized $383M IPO to push a Hengrui-licensed heart drug into Phase 3, where it would compete with Bristol Myers and Cytokinetics.
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics' Myqorzo in cardiomyopathy.
endpoints.news
August 6, 2026 at 2:31 PM
stocktitan.net
#CYTK Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

https://www.stocktitan.net/news/CYTK/cytokinetics-reports-first-quarter-2026-financial-results-and-jagd42s8x059.html
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
Cytokinetics (NASDAQ: CYTK) reported Q1 2026 results and a business update. Key items: U.S. launch of MYQORZO began Jan 27 with strong early demand, $4.8M net product revenue in ~9 weeks, ACACIA-HCM met dual primary endpoints in nHCM, European Commission approved MYQORZO for oHCM, and FDA set a PDUFA date of Nov 14, 2026 for MAPLE-HCM supplemental NDA.Financials: ~$1.1B cash and investments as of Mar 31, 2026; Q1 net loss of $206.0M. Company maintained full-year GAAP combined R&D and SG&A guidance of $830M–$870M.
www.stocktitan.net
May 5, 2026 at 8:05 PM
formdelta.bsky.social
📄 #CYTK 10-Q — what changed
MD&A now says: "In July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) granted MYQORZO marketing authorization across the United Kingdom for the treatment of symptomatic oHCM in adult patients."
📈 Full redline → https://www.formdelta.com/ticker/CYT
FormDelta — Insider Trading Alerts
What CYTOKINETICS INC changed in their own words, quarter over quarter.
www.formdelta.com
September 15, 2026 at 9:30 PM
medpagetoday.com
"Every way, shape, or form you look at this there was benefit." -- Ahmad Masri, MD, of @ohsunews.bsky.social Medical Group, discussing results from a trial of aficamten (Myqorzo) in symptomatic nonobstructive hypertrophic cardiomyopathy. #ESCCongress
www.medpagetoday.com/meetingcover...
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication
www.medpagetoday.com
September 8, 2026 at 2:11 PM
pharmaphorum.bsky.social
Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of #Myqorzo in non-obstructive hypertrophic cardiomyopathy at #ESC2026.
ESC26: Cytokinetics' big data reveal for Myqorzo impresses
Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026
pharmaphorum.com
August 31, 2026 at 1:54 PM
endpts.com
Cytokinetics eyes a broader Myqorzo label with new data in hand.
endpoints.news/esc26-data-i...
Data in hand, Cytokinetics looks to expanded Myqorzo approval
Cytokinetics' Myqorzo shows positive ACACIA-HCM trial data for nHCM at ESC, potentially doubling market reach; priced at $108,400 per year, competing with BMS' Camzyos.
endpoints.news
August 28, 2026 at 5:26 PM
medpagetoday.com
Treatment with aficamten (Myqorzo) improved exercise capacity as well as health status and symptoms in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in a large, double-blind, placebo-controlled trial. #ESCCongress
https://www.medpagetoday.com/meetingcoverage/esc/122812
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication
www.medpagetoday.com
August 28, 2026 at 7:36 PM
endpts.com
Cytokinetics sues Bristol Myers over patents, escalating their rivalry.
endpoints.news/cytokinetics...
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
Cytokinetics sued Bristol Myers Squibb to invalidate a patent on Camzyos, claiming it unfairly targets its rival heart drug Myqorzo (aficamten).
endpoints.news
August 14, 2026 at 8:27 PM
marketwire.bsky.social
📰 #Finance
Cytokinetics targets >50% MYQORZO new-to-brand share by end of 2026 while planning nHCM sNDA in Q4
seekingalpha.com
August 7, 2026 at 3:24 AM
signalbloom.ai
Cytokinetics' MYQORZO Launch Annihilates Estimates, But Soaring Launch Costs Widen Losses https://signalbloom.ai/news/CYTK/cytokinetics-myqorzo-launch-annihilates-estimates-but-soaring-launch-costs-widen-losses $CYTK #Earnings via @signalbloom.ai
August 6, 2026 at 8:23 PM
ipharmaservices.bsky.social
Il NHS ha approvato aficamten (Myqorzo) per la cardiomiopatia ipertrofica ostruttiva. Circa 6600 adulti in #Inghilterra potrebbero accedere più rapidamente a questo inibitore della miosina cardiaca a somministrazione quotidiana tramite il #NHS.
www.ipharmacenter.com/post/uk-gree...
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:20 AM
ipharmaservices.bsky.social
NHS have cleared aficamten (Myqorzo) for obstructive HCM. Around 6600 adults in #England could gain faster #NHS access to the once-daily cardiac myosin inhibitor.
www.ipharmacenter.com/post/uk-gree...
#Aficamten #HCM #Cardiology #NHS #UKHealth #HeartFailure #PharmaNews
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:15 AM
ipharmaservices.bsky.social
El NHS ha autorizado aficamtén (Myqorzo) para la miocardiopatía hipertrófica obstructiva. Unas 6600 personas en #Inglaterra podrían acceder antes a este inhibidor de la miosina cardíaca de toma diaria.
www.ipharmacenter.com/post/uk-gree...
#Aficamtén #HCM #Cardiología #NHS #SaludReinoUnido
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:16 AM
ipharmaservices.bsky.social
NHS ने ओब्सट्रक्टिव HCM के लिए अफिकाम्टेन (Myqorzo) को मंजूरी दी है। #इंग्लैंड के लगभग 6600 वयस्क रोगियों को #NHS के तहत इस एक बार दैनिक कार्डियक मायोसिन इनहिबिटर तक तेज़ी से पहुंच मिल सकती है।
www.ipharmacenter.com/post/uk-gree...
#अफिकाम्टेन #HCM #कार्डियोलॉजी #NHS #यूकेस्वास्थ्य #हृदयअपमान #फार्मा_न्यूज़
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:22 AM
ipharmaservices.bsky.social
NHS 가 폐색성 비대성 심근병증에 아피캄텐(Myqorzo) 을 승인했습니다. #잉글랜드의 약 6600 명 성인이 #NHS 를 통해 1 일 1 회 복용하는 심근 미오신 억제제에 더 빨리 접근할 수 있을 전망입니다.
www.ipharmacenter.com/post/uk-gree...
#아피캄텐 #HCM #심장혈관 #NHS #영국의료 #심부전 #제약뉴스
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:21 AM
ipharmaservices.bsky.social
O NHS aprovou o aficamten (Myqorzo) para a miocardiopatia hipertrofica obstrutiva. Cerca de 6600 adultos na #Inglaterra poderão ter acesso mais rápido a este inibidor da miosina cardíaca de toma diária através do #NHS.
www.ipharmacenter.com/post/uk-gree...
#Aficamten #HCM #Cardiologia #NHS
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:21 AM
pharmaphorum.bsky.social
#Cytokinetics is one of the first drugmakers to benefit from the #UK's dual #regulatory and #reimbursement appraisals, getting a green light for its #obstructivehypertrophic ardiomyopathy (HCM) drug #Myqorzo.
Cytokinetics' cardiomyopathy drug cleared for NHS use
Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.
buff.ly
July 30, 2026 at 2:30 PM